WuXi AppTec’s International Reach: Supporting Partners Across Asia, Europe, and North America

Shanghai, China Oct 26, 2025  – In recent years, the pharmaceutical and life sciences sector has increasingly emphasized international cooperation. Innovation is becoming more reliant on research and development organizations that operate through interconnected global networks. WuXi AppTec exemplifies this trend with its extensive presence across Asia, Europe, and North America. Its evolution from a single facility to a worldwide network demonstrates how broad geographical reach, supported by a Contract Research, Development and Manufacturing Organization (CRDMO) model, can link discovery and development on an international scale.

WuXi AppTec’s Global Reach: Operations Across Three Continents

Today, WuXi AppTec operates across Asia, Europe, and North America, with facilities located in China, Germany, Japan, Singapore, South Korea, Switzerland, and the United States. This expansive global network forms part of a CRDMO platform designed to integrate all key stages of drug development.

Harmonizing Regional Strengths

In Europe, the Munich site in Germany specializes in early-stage discovery, including areas such as biophysical analysis, crystallography, and protein science. The Couvet site in Switzerland complements this by focusing on late-stage clinical and commercial production, offering adaptable manufacturing and packaging solutions. Across North America, operations in San Diego and New Jersey provide support for biology, pharmacology, and testing programs. Collectively, these facilities illustrate how specialized regional expertise is interwoven through the CRDMO framework, enabling projects to advance seamlessly through various development phases within a unified network.

WuXi AppTec’s Growing Presence in Asia

In addition to its established locations, WuXi AppTec is expanding further into Asia. A significant instance is the Singapore site, where WuXi AppTec broke ground in May 2024 to construct a new R&D and manufacturing facility, with its Phase I operations projected to begin in 2027. This new 50-acre Singapore campus, situated within the dynamic Tuas Biomedical Park, is planned to house a total of seven plants at full capacity, providing CRDMO services for small molecules, oligonucleotides, peptides, and complex synthetic conjugates. As a vital component of the company’s worldwide network, the Singapore site will closely integrate with WuXi AppTec’s existing facilities across Asia, Europe, and North America, delivering effective CRDMO solutions for new drug R&D from initial discovery through commercialization, with enhanced flexibility and scalability.

The Tangible Benefits of a Global Network

Operating across three continents enables WuXi AppTec to uphold its CRDMO model, wherein research, development, and manufacturing are treated as interconnected stages rather than disparate functions. This integrated CRDMO approach fosters efficiency by mitigating transfer risks, accelerating timelines, and reducing obstacles for innovators. A global presence also streamlines coordination with regulatory bodies and facilitates the exchange of expertise across scientific communities. Both emerging biotech ventures and established pharmaceutical corporations can leverage this framework, as it ensures continuity from early discovery to commercial manufacturing. By embedding the CRDMO model into its operations, WuXi AppTec demonstrates how worldwide networks can expedite the delivery of novel therapies.

Facilitating Global Advancements in Healthcare

WuXi AppTec’s CRDMO model, underpinned by its extensive global network, consolidates research, development, and manufacturing onto a single platform. This methodology allows clients to initiate projects in one region and continue them in another without the need to duplicate infrastructure or change providers, thereby minimizing transfer risks and shortening development timelines. By integrating this model into a global network, WuXi AppTec empowers innovators to scale their work more efficiently and maintain uninterrupted progress from early discovery to commercial production. Serving a client base of thousands of partners worldwide, this combination of global reach and integrated capabilities exemplifies how an international platform can drive innovation while ensuring development remains closely aligned with patient needs.